Effects of GLP-1 receptor agonists on asprosin levels in normal weight or overweight/obesity patients with type 2 diabetes mellitus

Inflammation in obesity, diabetes, and related disorders

(2022) Theresa V. Rohm et al.   IMMUNITY

GLP-1 – Incretin and pleiotropic hormone with pharmacotherapy potential. Increasing secretion of endogenous GLP-1 for diabetes and obesity therapy

(2022) Jens Juul Holst et al.   CURRENT OPINION IN PHARMACOLOGY

High Serum Asprosin Levels Are Associated with Presence of Metabolic Syndrome

(2021) Tao Hong et al.   International Journal of Endocrinology

Obesity and insulin resistance: Pathophysiology and treatment

(2021) Yue Tong et al.   DRUG DISCOVERY TODAY

Liraglutide for Weight Management in the Real World: Significant Weight Loss Even if the Maximal Daily Dose Is Not Achieved

(2021) Liesbet Trenson et al.   Obesity Facts

Energy Regulation Mechanism and Therapeutic Potential of Asprosin

(2020) Jennifer G. Hoffmann et al.   DIABETES

Serum concentration of asprosin in new-onset type 2 diabetes

(2020) Shakiba Naiemian et al.   Diabetology & Metabolic Syndrome

Comparative effectiveness of dulaglutide versus liraglutide in Asian type 2 diabetes patients: a multi-institutional cohort study and meta-analysis

(2020) Kai-Cheng Chang et al.   Cardiovascular Diabetology

Effect of liraglutide on blood pressure: a meta-analysis of liraglutide randomized controlled trials

(2019) Xu Zhao et al.   BMC Endocrine Disorders

Aerobic Exercise Training Decreases Hepatic Asprosin in Diabetic Rats

(2019) Jeong Rim Ko et al.   Journal of Clinical Medicine

Direct and indirect effects of liraglutide on hypothalamic POMC and NPY/AgRP neurons – Implications for energy balance and glucose control

(2019) Zhenyan He et al.   Molecular Metabolism

Glucagon-like peptide 1 (GLP-1)

(2019) T.D. Müller et al.   Molecular Metabolism

Increased serum level and impaired response to glucose fluctuation of asprosin is associated with type 2 diabetes mellitus

(2019) Xinyue Zhang et al.   Journal of Diabetes Investigation

Mechanisms of Action and Therapeutic Application of Glucagon-like Peptide-1

(2018) Daniel J. Drucker   Cell Metabolism

Plasma Asprosin Concentrations Are Increased in Individuals with Glucose Dysregulation and Correlated with Insulin Resistance and First-Phase Insulin Secretion

(2018) Yuren Wang et al.   MEDIATORS OF INFLAMMATION

Propensity for Intra-abdominal and Hepatic Adiposity Varies Among Ethnic Groups

(2018) Unhee Lim et al.   GASTROENTEROLOGY

Effects of the glucagon-like peptide-1 receptor agonist liraglutide on 24-h ambulatory blood pressure in patients with type 2 diabetes and stable coronary artery disease

(2017) Preman Kumarathurai et al.   JOURNAL OF HYPERTENSION

Type 2 diabetes

(2017) Sudesna Chatterjee et al.   LANCET

Insulin action and resistance in obesity and type 2 diabetes

(2017) Michael P Czech   NATURE MEDICINE

Asprosin is a centrally acting orexigenic hormone

(2017) Clemens Duerrschmid et al.   NATURE MEDICINE

Circulating asprosin concentrations are increased in type 2 diabetes mellitus and independently associated with fasting glucose and triglyceride

(2017) Lei Zhang et al.   CLINICA CHIMICA ACTA

Asprosin, a Fasting-Induced Glucogenic Protein Hormone

(2016) Chase Romere et al.   CELL

Efficacy of Liraglutide for Weight Loss Among Patients With Type 2 Diabetes

(2015) Melanie J. Davies et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Glucose-Lowering Effects and Low Risk of Hypoglycemia in Patients With Maturity-Onset Diabetes of the Young When Treated With a GLP-1 Receptor Agonist: A Double-Blind, Randomized, Crossover Trial

(2014) Signe H. Østoft et al.   DIABETES CARE